The chemotherapy of colon cancer can no longer be ignored

European Journal of Cancer

Volumn 29, Issue 15, 1993, Pages 2077-2079

  Cunningham, D ^a   Findlay, M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; PYRIDOXINE; SEMUSTINE; SPARFOSIC ACID; VINCRISTINE;

CANCER CHEMOTHERAPY; COLON CANCER; CRYOTHERAPY; ERYTHEMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NOTE; PRIORITY JOURNAL; REGIONAL PERFUSION; STOMATITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMAN; INFUSIONS, INTRAVENOUS; LEUCOVORIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0027379619     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(93)90036-F     Document Type: Note

References (25)

1. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
2. The Intergroup study of fluorouracil (5FU) plus levamisole and levamisole alone as adjuvant therapy for stage C colon cancer. A final report
3. Leucovorin-modulated 5-FU (LV-FU) as adjuvant therapy for primary colon cancer: NSABP C-03
4. An Intergroup trial of intensive course 5FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer
5. FUFA increases disease free survival (DFS) in resected B2C colon cancer (CC): results of a prospective pooled analysis of 3 randomised trials (RCT's)
6. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
7. Cryotherapy for prevention of 5-fluorouracil induced mucositis
8. Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma
9. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma
10. Active life expectancy
11. A randomised controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer
12. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma
13. Adjuvant therapy of Dukes A, B and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of national surgical adjuvant breast and bowel project protocol C-02
14. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
15. Adjuvant intraportal chemotherapy for colorectal cancer—8 year results of the randomised swiss trial (SAKK 40/81)
16. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.
17. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
18. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate
19. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
20. A prospectively randomised clinical trial comparing 5FU combined with either high or low dose leucovorin for the treatment of advanced colorectal cancer
21. 19F magnetic resonance spectroscopy: correlation with clinical effects and implications for further clinical trials
22. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma
23. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study
24. Treatment of patients with locally advanced pancreatic carcinoma with continuous infusion (CI), 5-fluorouracil (5FU), calcium leucovorin (LV), mitomycin-C (Mito-C) and dipyridamole (D)
25. Phase II study of CPT-11, new camptothecin derivative in the patients with metastatic colorectal cancer